$BMRN Recent News BioMarin shares rally as FDA mutes

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 2:42 PM

$BMRN Recent News

BioMarin shares rally as FDA mutes criticism of rare disorder drug 5:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 11:10 a.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 5:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 10:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 12:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 2:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 4:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 11:56 a.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 12:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 11:39 a.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 12:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 11:17 a.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 11:49 a.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 6:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 9:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 9:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Corrective bounce, or sustainable upturn? 10:51 a.m. July 13, 2012 - Michael Ashbaugh
Bears come to life on jobs report 9:14 a.m. July 6, 2012 - Michael Ashbaugh

Insider Trading Alert - GNW, WFC, LII, WDR And BMRN Traded By Insiders 10:30 a.m. Dec. 12, 2013 - TheStreet.com
Orphan Drug Designations: Why You Should Care 10:23 a.m. Dec. 12, 2013 - Seeking Alpha
Myriad, Janssen Partner on BRACAnalysis - Analyst Blog 6:26 p.m. Dec. 10, 2013 - Zacks.com
Cramer's Lightning Round - The Quintessential American Stock That Is Going To Work (12/9/13) 6:01 a.m. Dec. 10, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Get Serious on Sirius 6:00 a.m. Dec. 10, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Rally Rules 8:20 p.m. Dec. 9, 2013 - TheStreet.com
BioMarin Seeks Canadian Approval - Analyst Blog 11:50 a.m. Dec. 5, 2013 - Zacks.com
BioMarin Submits VIMIZIM(TM) (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status 8:00 a.m. Dec. 4, 2013 - CNW Group
BioMarin Pharmaceutical's Management Presents at 2013 Deutsche Bank BioFEST Conference (Transcript) 2:20 p.m. Dec. 3, 2013 - Seeking Alpha
Galena: A Pipeline Rich For Investors 2:46 a.m. Dec. 2, 2013 - Seeking Alpha
Biomarin Pharmaceutical Inc. Stock Upgraded (BMRN) 10:12 a.m. Nov. 29, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns 10:10 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook 6:50 a.m. Nov. 27, 2013 - benzinga.com
Myriad, BioMarin Collaborate Again - Analyst Blog 5:05 p.m. Nov. 22, 2013 - Zacks.com
Amicus' 'Transformative" Changes Look More Like Big Step Backward 7:37 p.m. Nov. 20, 2013 - TheStreet.com
Jim Cramer's 6 Stocks in 60 Seconds: DKS COG WDAY BMRN DWRE TSLA (Update 1) 5:09 p.m. Nov. 20, 2013 - TheStreet.com
BioMarin Pharmaceutical Larger Than S&P 500 Component Linear Technology 4:44 p.m. Nov. 20, 2013 - TheStreet.com
Analysts: BioMarin Will Trade Up on Panel Vote and 3 More Research Notes to Browse 3:02 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet

Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living 8:00 a.m. Dec. 12, 2013 - PR Newswire
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc. 10:19 a.m. Dec. 11, 2013 - PR Newswire
Stock Price Updates, and Charitable Contributions - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Dec. 4, 2013 - PR Newswire
Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika Therapeutics, and Exelis 8:00 a.m. Dec. 3, 2013 - PR Newswire
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Nov. 26, 2013 - PR Newswire
Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston 5:10 a.m. Nov. 26, 2013 - GlobeNewswire
FDA Approvals, Public Offerings and Stock Price Movements - Research Report on BioMarin, AEterna Zentaris, Charles River, Anika Therapeutics and Halozyme Therapeutics 8:00 a.m. Nov. 25, 2013 - PR Newswire
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar 8:00 a.m. Nov. 20, 2013 - PR Newswire
FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome 5:02 p.m. Nov. 19, 2013 - GlobeNewswire
BioMarin Stock Trading Halted Today 7:10 a.m. Nov. 19, 2013 - GlobeNewswire
FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome 9:15 a.m. Nov. 15, 2013 - GlobeNewswire
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc. 8:00 a.m. Nov. 15, 2013 - PR Newswire
BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome 7:59 a.m. Nov. 15, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference 8:30 a.m. Nov. 5, 2013 - GlobeNewswire
Critical Alerts For Citigroup, Community Health, Oracle, Boeing, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Nov. 1, 2013 - PR Newswire
Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax 9:00 a.m. Oct. 31, 2013 - PR Newswire
BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer 5:00 a.m. Oct. 31, 2013 - GlobeNewswire
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc. 11:34 a.m. Oct. 25, 2013 - PR Newswire
BioMarin Announces Third Quarter 2013 Financial Results 5:33 p.m. Oct. 24, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....